Becton, Dickinson and Company (BMV:BDX)
Mexico · Delayed Price · Currency is MXN 3,535.21
+181.62 (5.42%)
At close: Dec 5, 2025
Revenue Breakdown
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | Sep '19 Sep 30, 2019 | Sep '18 Sep 30, 2018 | Sep '17 Sep 30, 2017 | Sep '16 Sep 30, 2016 | Sep '15 Sep 30, 2015 | Sep '14 Sep 30, 2014 | Sep '13 Sep 30, 2013 | Sep '12 Sep 30, 2012 |
Medication Delivery Solutions Revenue | 4.58B | 4.58B | 4.43B | ||||||||||||
Medication Delivery Solutions Revenue Growth | 0.09% | 3.30% | 3.17% | ||||||||||||
Medication Management Solutions Revenue | 3.51B | 3.47B | 3.30B | ||||||||||||
Medication Management Solutions Revenue Growth | 0.98% | 5.37% | 10.64% | ||||||||||||
Pharmaceutical Systems Revenue | 2.34B | 2.32B | 2.27B | ||||||||||||
Pharmaceutical Systems Revenue Growth | 0.47% | 2.24% | 1.97% | ||||||||||||
Advanced Patient Monitoring Revenue | 1.11B | 1.08B | 74.00M | ||||||||||||
Advanced Patient Monitoring Revenue Growth | 2.40% | 1362.16% | - | ||||||||||||
Specimen Management Revenue | 1.88B | 1.87B | 1.83B | ||||||||||||
Specimen Management Revenue Growth | 0.32% | 2.07% | - | ||||||||||||
Diagnostic Solusions Revenue | 1.80B | 1.84B | 1.85B | ||||||||||||
Diagnostic Solusions Revenue Growth | -1.96% | -0.43% | - | ||||||||||||
Integrated Diagnostic Solutions Revenue | 3.68B | 3.71B | 3.68B | ||||||||||||
Integrated Diagnostic Solutions Revenue Growth | -0.81% | 0.81% | 1.52% | ||||||||||||
Biosciences Revenue | 1.42B | 1.46B | 1.51B | ||||||||||||
Biosciences Revenue Growth | -2.33% | -3.57% | 0.20% | ||||||||||||
Surgery Revenue | 1.60B | 1.57B | 1.49B | ||||||||||||
Surgery Revenue Growth | 1.53% | 5.36% | -0.33% | ||||||||||||
Peripheral Intervention Revenue | 2.01B | 2.00B | 1.93B | ||||||||||||
Peripheral Intervention Revenue Growth | 0.60% | 3.26% | 3.65% | ||||||||||||
Urology and Critical Care Revenue | 1.69B | 1.65B | 1.55B | ||||||||||||
Urology and Critical Care Revenue Growth | 2.24% | 6.11% | 13.10% | ||||||||||||
Revenue (Other) | -3.68B | -3.71B | -3.74B | ||||||||||||
Revenue (Total) | 21.92B | 21.84B | 20.18B | ||||||||||||
Revenue (Total) Growth | 0.39% | 8.24% | 4.16% |
Revenue by Geography
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | Sep '19 Sep 30, 2019 | Sep '18 Sep 30, 2018 | Sep '17 Sep 30, 2017 | Sep '16 Sep 30, 2016 | Sep '15 Sep 30, 2015 | Sep '14 Sep 30, 2014 | Sep '13 Sep 30, 2013 | Sep '12 Sep 30, 2012 |
United States Revenue | 12.87B | 12.79B | 11.66B | ||||||||||||
United States Revenue Growth | 0.62% | 9.66% | 4.95% | ||||||||||||
International Revenue | 9.05B | 9.05B | 8.52B | ||||||||||||
International Revenue Growth | 0.04% | 6.27% | 3.11% | ||||||||||||
Revenue (Other) | 2.00M | 1.00M | - | ||||||||||||
Revenue (Total) | 21.92B | 21.84B | 20.18B | ||||||||||||
Revenue (Total) Growth | 0.39% | 8.24% | 4.16% |
Revenue Breakdown 3
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | Sep '19 Sep 30, 2019 | Sep '18 Sep 30, 2018 | Sep '17 Sep 30, 2017 | Sep '16 Sep 30, 2016 | Sep '15 Sep 30, 2015 | Sep '14 Sep 30, 2014 | Sep '13 Sep 30, 2013 | Sep '12 Sep 30, 2012 |
Medical Revenue | - | 11.46B | 10.07B | ||||||||||||
Medical Revenue Growth | - | 13.72% | 6.02% | ||||||||||||
Life Sciences Revenue (Pre-FY2026 Reporting) | - | 5.17B | 5.19B | ||||||||||||
Life Sciences Revenue (Pre-FY2026 Reporting) Growth | - | -0.46% | 1.13% | ||||||||||||
Interventional Revenue (Pre-FY2026 Reporting) | - | 5.22B | 4.98B | ||||||||||||
Interventional Revenue (Pre-FY2026 Reporting) Growth | - | 4.76% | 5.15% | ||||||||||||
Revenue (Total) | 21.92B | 21.84B | 20.18B | ||||||||||||
Revenue (Total) Growth | 0.39% | 8.24% | 4.16% |
EBIT 2
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | Sep '19 Sep 30, 2019 | Sep '18 Sep 30, 2018 | Sep '17 Sep 30, 2017 | Sep '16 Sep 30, 2016 | Sep '15 Sep 30, 2015 | Sep '14 Sep 30, 2014 | Sep '13 Sep 30, 2013 | Sep '12 Sep 30, 2012 |
Medical Segment Operating Income | - | - | 2.74B | ||||||||||||
Medical Segment Operating Income Growth | - | - | 39.40% | ||||||||||||
Life Sciences Segment Operating Income (Pre-FY2026 Reporting) | - | - | 1.60B | ||||||||||||
Life Sciences Segment Operating Income (Pre-FY2026 Reporting) Growth | - | - | 0.63% | ||||||||||||
Interventional Segment Operating Income (Pre-FY2026 Reporting) | - | - | 1.42B | ||||||||||||
Interventional Segment Operating Income (Pre-FY2026 Reporting) Growth | - | - | 16.68% | ||||||||||||
Operating Income (Total) | 2.68B | 2.58B | 2.40B | ||||||||||||
Operating Income (Total) Growth | 3.80% | 7.59% | 13.55% |
Updated Dec 31, 2025. Data Source: Fiscal.ai.